Header Logo

Connection

James Mulshine to Lung Neoplasms

Back to Details
This is a "connection" page, showing publications James Mulshine has written about Lung Neoplasms.
James Mulshine
Connection Strength
18.443
Lung Neoplasms
  1. Emphysema Detection in the Course of Lung Cancer Screening: Optimizing a Rare Opportunity to Impact Population Health. Ann Am Thorac Soc. 2023 04; 20(4):499-503.
    View in: PubMed
    Score: 0.597
  2. The Long, Slow Road to Lung Cancer Cure. JAMA Oncol. 2021 12 01; 7(12):1765-1767.
    View in: PubMed
    Score: 0.545
  3. Thoracic CT screening: using routinely detectable COPD information. Clin Imaging. 2021 Oct; 78:310-312.
    View in: PubMed
    Score: 0.523
  4. The International Association for the Study of Lung Cancer Early Lung Imaging Confederation. JCO Clin Cancer Inform. 2020 02; 4:89-99.
    View in: PubMed
    Score: 0.480
  5. One Screening for Ischemic Heart Disease, Lung Cancer, and Chronic Obstructive Pulmonary Disease: A Systems Biology Bridge for Tobacco and Radiation Exposure. Am J Public Health. 2018 10; 108(10):1294-1295.
    View in: PubMed
    Score: 0.437
  6. Lung Cancer Workshop XI: Tobacco-Induced Disease: Advances in Policy, Early Detection and Management. J Thorac Oncol. 2015 May; 10(5):762-767.
    View in: PubMed
    Score: 0.345
  7. Role of the Quantitative Imaging Biomarker Alliance in optimizing CT for the evaluation of lung cancer screen-detected nodules. J Am Coll Radiol. 2015 Apr; 12(4):390-5.
    View in: PubMed
    Score: 0.343
  8. Shared decision making and screening: an ongoing dialogue informed by data. Oncology (Williston Park). 2015 Mar; 29(3):149.
    View in: PubMed
    Score: 0.341
  9. Lung cancer screening with low-dose CT: more questions than answers--author's reply. Lancet Oncol. 2015 Jan; 16(1):e4.
    View in: PubMed
    Score: 0.337
  10. Evaluation of an interactive science publishing tool: toward enabling three-dimensional analysis of medical images. Acad Radiol. 2015 Mar; 22(3):380-6.
    View in: PubMed
    Score: 0.336
  11. Lung cancer screening: achieving more by intervening less. Lancet Oncol. 2014 Nov; 15(12):1284-5.
    View in: PubMed
    Score: 0.331
  12. Issues with implementing a high-quality lung cancer screening program. CA Cancer J Clin. 2014 Sep-Oct; 64(5):352-63.
    View in: PubMed
    Score: 0.325
  13. Tobacco control since the 1964 Surgeon General's Report: reflecting back and looking forward. Oncology (Williston Park). 2014 Mar; 28(3):180, 182-3, 210.
    View in: PubMed
    Score: 0.318
  14. Application of high-resolution CT imaging data to lung cancer drug development: measuring progress: workshop IX. J Thorac Oncol. 2013 Nov; 8(11):1352-5.
    View in: PubMed
    Score: 0.311
  15. Advancing patient-centric genomic medicine. Oncology (Williston Park). 2013 Sep; 27(9):827.
    View in: PubMed
    Score: 0.307
  16. Lessons from considering the cancer landscape. Oncology (Williston Park). 2013 May; 27(5):408, 410.
    View in: PubMed
    Score: 0.300
  17. An actuarial analysis shows that offering lung cancer screening as an insurance benefit would save lives at relatively low cost. Health Aff (Millwood). 2012 Apr; 31(4):770-9.
    View in: PubMed
    Score: 0.279
  18. Lung cancer screening: what is the benefit and what do we do about it? Lung Cancer. 2011 Mar; 71(3):247-8.
    View in: PubMed
    Score: 0.257
  19. hnRNP A2/B1 modulates epithelial-mesenchymal transition in lung cancer cell lines. Cancer Res. 2010 Sep 15; 70(18):7137-47.
    View in: PubMed
    Score: 0.250
  20. Introduction: Imaging in diagnosis and treatment of lung cancer. Opt Express. 2010 Jul 05; 18(14):15242-3.
    View in: PubMed
    Score: 0.247
  21. A quantitative method for estimating individual lung cancer risk. Acad Radiol. 2010 Jul; 17(7):830-40.
    View in: PubMed
    Score: 0.247
  22. Cytokines and growth factors stimulate hyaluronan production: role of hyaluronan in epithelial to mesenchymal-like transition in non-small cell lung cancer. J Biomed Biotechnol. 2010; 2010:485468.
    View in: PubMed
    Score: 0.247
  23. Lung cancer and inflammation: interaction of chemokines and hnRNPs. Curr Opin Pharmacol. 2009 Aug; 9(4):384-8.
    View in: PubMed
    Score: 0.230
  24. Use of high-resolution CT imaging data in lung cancer drug development: measuring progress. Oncology (Williston Park). 2009 Apr 30; 23(5):434-8.
    View in: PubMed
    Score: 0.228
  25. Commentary: lung cancer screening--progress or peril. Oncologist. 2008 Apr; 13(4):435-8.
    View in: PubMed
    Score: 0.211
  26. Developing CT image-processing tools to accelerate progress in lung cancer drug development. Oncology (Williston Park). 2006 Nov; 20(12):1606, 1608-10, 1614 passim.
    View in: PubMed
    Score: 0.191
  27. Early lung cancer detection: approaching the 'tipping point'? Oncology (Williston Park). 2006 Nov; 20(12):1632.
    View in: PubMed
    Score: 0.191
  28. The Liverpool Statement 2005: priorities for the European Union/United States spiral computed tomography collaborative group. J Thorac Oncol. 2006 Jun; 1(5):497-8.
    View in: PubMed
    Score: 0.186
  29. Lung cancer screening. Oncologist. 2006 May; 11(5):481-7.
    View in: PubMed
    Score: 0.185
  30. Current issues in lung cancer screening. Oncology (Williston Park). 2005 Nov; 19(13):1724-30; discussion 1730-1.
    View in: PubMed
    Score: 0.179
  31. Clinical issues in the management of early lung cancer. Clin Cancer Res. 2005 Jul 01; 11(13 Pt 2):4993s-4998s.
    View in: PubMed
    Score: 0.175
  32. Clinical practice. Lung cancer screening. N Engl J Med. 2005 Jun 30; 352(26):2714-20.
    View in: PubMed
    Score: 0.174
  33. Inhibitors of the arachidonic acid pathway and peroxisome proliferator-activated receptor ligands have superadditive effects on lung cancer growth inhibition. Cancer Res. 2005 May 15; 65(10):4181-90.
    View in: PubMed
    Score: 0.173
  34. New developments in lung cancer screening. J Clin Oncol. 2005 May 10; 23(14):3198-202.
    View in: PubMed
    Score: 0.173
  35. Lung cancer screening: panacea or pipe dream? Ann Oncol. 2005; 16 Suppl 2:ii215-9.
    View in: PubMed
    Score: 0.169
  36. Epithelial-directed drug delivery: influence of formulation and delivery devices. Lung Cancer. 2004 Dec; 46(3):387-92.
    View in: PubMed
    Score: 0.168
  37. Is the gene expression pattern of lung cancer detected by screening with spiral computed tomography different from that of symptom-detected lung cancer? Clin Cancer Res. 2004 Sep 15; 10(18 Pt 1):5973-4.
    View in: PubMed
    Score: 0.165
  38. Lung cancer screening with spiral CT: toward a working strategy. Oncology (Williston Park). 2004 May; 18(5):564-75, discussion 578, 583-4, 587.
    View in: PubMed
    Score: 0.161
  39. Surgical considerations with lung cancer screening. J Surg Oncol. 2003 Sep; 84(1):1-6.
    View in: PubMed
    Score: 0.154
  40. The International Association for the Study of Lung Cancer Early Lung Imaging Confederation Open-Source Deep Learning and Quantitative Measurement Initiative. J Thorac Oncol. 2024 Jan; 19(1):94-105.
    View in: PubMed
    Score: 0.153
  41. Lung cancer chemoprevention: moving from concept to a reality. Lung Cancer. 2003 Aug; 41 Suppl 1:S163-74.
    View in: PubMed
    Score: 0.153
  42. The potential contributions of chronic inflammation to lung carcinogenesis. Clin Lung Cancer. 2003 Jul; 5(1):46-62.
    View in: PubMed
    Score: 0.152
  43. Screening for lung cancer: in pursuit of pre-metastatic disease. Nat Rev Cancer. 2003 Jan; 3(1):65-73.
    View in: PubMed
    Score: 0.147
  44. Tobacco money: up in smoke? Lancet. 2002 Dec 14; 360(9349):1979-80; author reply 1981.
    View in: PubMed
    Score: 0.146
  45. Lung cancer. 2: screening and early diagnosis of lung cancer. Thorax. 2002 Dec; 57(12):1071-8.
    View in: PubMed
    Score: 0.146
  46. IV international conference on prevention and early detection of lung cancer, Reykjavik, Iceland, August 9-12, 2001. Lung Cancer. 2002 Sep; 37(3):325-44.
    View in: PubMed
    Score: 0.143
  47. Radiologic screening for lung cancer. Expert Rev Anticancer Ther. 2002 Aug; 2(4):385-92.
    View in: PubMed
    Score: 0.143
  48. Lung cancer evolution to preinvasive management. Clin Chest Med. 2002 Mar; 23(1):37-48.
    View in: PubMed
    Score: 0.138
  49. Moving to the routine management of pre symptomatic lung cancer. Lung Cancer. 2001 Dec; 34 Suppl 2:S1-5.
    View in: PubMed
    Score: 0.136
  50. Screening for lung cancer. N Engl J Med. 2001 Mar 22; 344(12):935-6.
    View in: PubMed
    Score: 0.130
  51. Considerations in developing successful, population-based molecular screening and prevention of lung cancer. Cancer. 2000 Dec 01; 89(11 Suppl):2465-7.
    View in: PubMed
    Score: 0.127
  52. Phenotypically different cells with heterogeneous nuclear ribonucleoprotein A2/B1 overexpression show similar genetic alterations. Am J Respir Cell Mol Biol. 2000 Nov; 23(5):636-45.
    View in: PubMed
    Score: 0.126
  53. The early detection of occult lung cancer. Chest Surg Clin N Am. 2000 Nov; 10(4):737-49.
    View in: PubMed
    Score: 0.126
  54. Inhaled isotretinoin (13-cis retinoic acid) is an effective lung cancer chemopreventive agent in A/J mice at low doses: a pilot study. Clin Cancer Res. 2000 Aug; 6(8):3015-24.
    View in: PubMed
    Score: 0.124
  55. Prospects for lung-cancer screening. Lancet. 2000 Feb 19; 355(9204):592-3.
    View in: PubMed
    Score: 0.120
  56. New molecular strategies for early lung cancer detection. Cancer Invest. 2000; 18(6):555-63.
    View in: PubMed
    Score: 0.119
  57. Reducing lung cancer risk: early detection. Chest. 1999 Dec; 116(6 Suppl):493S-496S.
    View in: PubMed
    Score: 0.119
  58. Phase I and imaging trial of a monoclonal antibody directed against gastrin-releasing peptide in patients with lung cancer. Clin Cancer Res. 1999 Nov; 5(11):3385-93.
    View in: PubMed
    Score: 0.118
  59. Lipoxygenase inhibitors prevent lung carcinogenesis and inhibit non-small cell lung cancer growth. Exp Lung Res. 1998 Jul-Aug; 24(4):617-28.
    View in: PubMed
    Score: 0.107
  60. Quality assurance and quantitative imaging biomarkers in low-dose CT lung cancer screening. Br J Radiol. 2018 Oct; 91(1090):20170401.
    View in: PubMed
    Score: 0.102
  61. Sputum screening by quantitative microscopy: a new dawn for detection of lung cancer? Mayo Clin Proc. 1997 Aug; 72(8):788-90.
    View in: PubMed
    Score: 0.101
  62. Recent molecular advances in the approach to early lung cancer detection and intervention. Environ Health Perspect. 1997 Jun; 105 Suppl 4:935-9.
    View in: PubMed
    Score: 0.100
  63. Prevention and early detection of lung cancer-clinical aspects. Lung Cancer. 1997 May; 17(1):163-74.
    View in: PubMed
    Score: 0.099
  64. New approaches to the integrated management of early lung cancer. Hematol Oncol Clin North Am. 1997 Apr; 11(2):235-52.
    View in: PubMed
    Score: 0.099
  65. High frequency of K-ras codon 12 mutations in bronchoalveolar lavage fluid of patients at high risk for second primary lung cancer. Clin Cancer Res. 1997 Mar; 3(3):479-82.
    View in: PubMed
    Score: 0.098
  66. Lung cancer: current therapies and new targeted treatments. Lancet. 2017 01 21; 389(10066):299-311.
    View in: PubMed
    Score: 0.095
  67. Volumes Learned: It Takes More Than Size to "Size Up" Pulmonary Lesions. Acad Radiol. 2016 09; 23(9):1190-8.
    View in: PubMed
    Score: 0.093
  68. Peptide amidating activity in human bronchoalveolar lavage fluid. Lung Cancer. 1996 Jun; 14(2-3):239-51.
    View in: PubMed
    Score: 0.093
  69. Growth control of lung cancer by interruption of 5-lipoxygenase-mediated growth factor signaling. J Clin Invest. 1996 Feb 01; 97(3):806-13.
    View in: PubMed
    Score: 0.091
  70. Transferrin dependence of Ga (NO3)3 inhibition of growth in human-derived small cell lung cancer cells. J Cell Biochem Suppl. 1996; 24:276-87.
    View in: PubMed
    Score: 0.090
  71. Molecular markers in early cancer detection. New screening tools. Chest. 1995 Jun; 107(6 Suppl):280S-286S.
    View in: PubMed
    Score: 0.087
  72. Anticancer antibodies for lung cancer. J Clin Oncol. 1994 Nov; 12(11):2519-20.
    View in: PubMed
    Score: 0.083
  73. RB protein status and clinical correlation from 171 cell lines representing lung cancer, extrapulmonary small cell carcinoma, and mesothelioma. Oncogene. 1994 Sep; 9(9):2441-8.
    View in: PubMed
    Score: 0.082
  74. Integrated clinical and basic studies related to circumventing non-small cell lung cancer drug resistance. Lung Cancer. 1994 Mar; 10 Suppl 1:S73-81.
    View in: PubMed
    Score: 0.080
  75. The International Association Study Lung Cancer (IASLC) Strategic Screening Advisory Committee (SSAC) response to the USPSTF recommendations. J Thorac Oncol. 2014 Feb; 9(2):141-3.
    View in: PubMed
    Score: 0.079
  76. Cytometric validation of immunocytochemical observations in developing lung cancer. Diagn Cytopathol. 1993 Dec; 9(6):615-22.
    View in: PubMed
    Score: 0.078
  77. Biochemical characterization of peptide alpha-amidation enzyme activities of human neuroendocrine lung cancer cell lines. Cell Growth Differ. 1993 Nov; 4(11):911-20.
    View in: PubMed
    Score: 0.078
  78. Early detection of lung cancer. Semin Oncol. 1993 Aug; 20(4):374-82.
    View in: PubMed
    Score: 0.076
  79. Monoclonal antibodies for early cytologic detection of lung cancer. Semin Thorac Cardiovasc Surg. 1993 Jul; 5(3):201-9.
    View in: PubMed
    Score: 0.076
  80. Epidemiology, prognostic factors, and prevention of lung cancer. Curr Opin Oncol. 1993 Mar; 5(2):302-9.
    View in: PubMed
    Score: 0.074
  81. Initiators and promoters of lung cancer. Chest. 1993 Jan; 103(1 Suppl):4S-11S.
    View in: PubMed
    Score: 0.073
  82. Prospective trial evaluating immunocytochemical-based sputum techniques for early lung cancer detection: assays for promotion factors in the bronchial lavage. J Cell Biochem Suppl. 1993; 17F:175-83.
    View in: PubMed
    Score: 0.073
  83. Development of The American Association for Thoracic Surgery guidelines for low-dose computed tomography scans to screen for lung cancer in North America: recommendations of The American Association for Thoracic Surgery Task Force for Lung Cancer Screening and Surveillance. J Thorac Cardiovasc Surg. 2012 Jul; 144(1):25-32.
    View in: PubMed
    Score: 0.071
  84. The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. J Thorac Cardiovasc Surg. 2012 Jul; 144(1):33-8.
    View in: PubMed
    Score: 0.071
  85. The correct dose: pharmacologically guided end point for anti-growth factor therapy. Cancer Res. 1992 May 01; 52(9 Suppl):2743s-2746s.
    View in: PubMed
    Score: 0.070
  86. Overview: NCI Workshop on Investigational Strategies for Detection and Intervention in Early Lung Cancer. Cancer Res. 1992 May 01; 52(9 Suppl):2639s-2640s.
    View in: PubMed
    Score: 0.070
  87. Considerations in bringing a cancer biomarker to clinical application. Cancer Res. 1992 May 01; 52(9 Suppl):2711s-2718s.
    View in: PubMed
    Score: 0.070
  88. Diagnostic research: breakout group report. Cancer Res. 1992 May 01; 52(9 Suppl):2766s.
    View in: PubMed
    Score: 0.070
  89. International Association for the Study of Lung Cancer Computed Tomography Screening Workshop 2011 report. J Thorac Oncol. 2012 Jan; 7(1):10-9.
    View in: PubMed
    Score: 0.068
  90. Rational targets for the early detection of lung cancer. J Natl Cancer Inst Monogr. 1992; (13):183-90.
    View in: PubMed
    Score: 0.068
  91. Growth factors and other targets for rational application as intervention agents. Adv Exp Med Biol. 1992; 320:81-8.
    View in: PubMed
    Score: 0.068
  92. Candidate biomarkers for application as intermediate end points of lung carcinogenesis. J Cell Biochem Suppl. 1992; 16G:183-6.
    View in: PubMed
    Score: 0.068
  93. Preclinical evaluation of an anti-autocrine growth factor monoclonal antibody for treatment of patients with small-cell lung cancer. J Natl Cancer Inst. 1991 Oct 16; 83(20):1470-6.
    View in: PubMed
    Score: 0.067
  94. Lung cancer: rational strategies for early detection and intervention. Oncology (Williston Park). 1991 May; 5(5):25-32; discussion 32-3, 37.
    View in: PubMed
    Score: 0.065
  95. Reconstituted basement membrane (matrigel) and laminin can enhance the tumorigenicity and the drug resistance of small cell lung cancer cell lines. Proc Natl Acad Sci U S A. 1990 Sep; 87(17):6698-702.
    View in: PubMed
    Score: 0.062
  96. A phase II trial of carboplatin (CBDCA) in small-cell and non-small-cell lung cancer with correlation to in vitro analysis of cytotoxicity. Am J Clin Oncol. 1990 Aug; 13(4):285-9.
    View in: PubMed
    Score: 0.062
  97. An actuarial approach to comparing early stage and late stage lung cancer mortality and survival. Popul Health Manag. 2010 Feb; 13(1):33-46.
    View in: PubMed
    Score: 0.060
  98. The use of volumetric CT as an imaging biomarker in lung cancer. Acad Radiol. 2010 Jan; 17(1):100-6.
    View in: PubMed
    Score: 0.060
  99. Autocrine growth factors as therapeutic targets in lung cancer. Chest. 1989 Jul; 96(1 Suppl):31S-34S.
    View in: PubMed
    Score: 0.058
  100. Considerations in the development of lung cancer screening tools. J Natl Cancer Inst. 1989 Jun 21; 81(12):900-6.
    View in: PubMed
    Score: 0.057
  101. In vivo diagnosis and therapy of human tumors with monoclonal antibodies: selection of antibodies and preliminary clinical studies in small cell carcinoma of the lung. Int J Rad Appl Instrum B. 1989; 16(2):159-62.
    View in: PubMed
    Score: 0.056
  102. Autocrine growth factors and lung cancer. Cancer Treat Res. 1989; 45:107-22.
    View in: PubMed
    Score: 0.056
  103. Sensitive and specific monoclonal antibody recognition of human lung cancer antigen on preserved sputum cells: a new approach to early lung cancer detection. J Clin Oncol. 1988 Nov; 6(11):1685-93.
    View in: PubMed
    Score: 0.055
  104. Lung cancer screening with low-dose computed tomography: a non-invasive diagnostic protocol for baseline lung nodules. Lung Cancer. 2008 Sep; 61(3):340-9.
    View in: PubMed
    Score: 0.053
  105. Clinical use of a monoclonal antibody to bombesin-like peptide in patients with lung cancer. Ann N Y Acad Sci. 1988; 547:360-72.
    View in: PubMed
    Score: 0.052
  106. Immunolymphoscintigraphy of pulmonary and mediastinal lymph nodes in dogs: a new approach to lung cancer imaging. Cancer Res. 1987 Jul 01; 47(13):3572-6.
    View in: PubMed
    Score: 0.050
  107. Treatment of non-small-cell lung cancer. J Clin Oncol. 1986 Nov; 4(11):1704-15.
    View in: PubMed
    Score: 0.048
  108. Radiographic imaging of bronchioloalveolar carcinoma: screening, patterns of presentation and response assessment. J Thorac Oncol. 2006 Nov; 1(9 Suppl):S20-6.
    View in: PubMed
    Score: 0.048
  109. Early stage lung cancer--new approaches to evaluation and treatment: conference summary statement. Clin Cancer Res. 2005 Jul 01; 11(13 Pt 2):4981s-4983s.
    View in: PubMed
    Score: 0.044
  110. Diagnosis and significance of liver metastases in small cell carcinoma of the lung. J Clin Oncol. 1984 Jul; 2(7):733-41.
    View in: PubMed
    Score: 0.041
  111. Monoclonal antibodies that distinguish non-small cell from small cell lung cancer. J Immunol. 1983 Jul; 131(1):497-502.
    View in: PubMed
    Score: 0.038
  112. Screening of mutations in the ras family of oncogenes by polymerase chain reaction-based ligase chain reaction. Methods Mol Med. 2003; 74:187-200.
    View in: PubMed
    Score: 0.037
  113. Lung cancer screening by spiral CT. What is the optimal target population for screening trials? Lung Cancer. 2002 Dec; 38(3):243-52.
    View in: PubMed
    Score: 0.036
  114. Consensus statements from the Second International Lung Cancer Molecular Biomarkers Workshop: a European strategy for developing lung cancer molecular diagnostics in high risk populations. Int J Oncol. 2002 Aug; 21(2):369-73.
    View in: PubMed
    Score: 0.036
  115. Expression of early lung cancer detection marker: hnRNP-A2/B1 and its relation to microsatellite alteration in non-small cell lung cancer. Lung Cancer. 2001 Dec; 34(3):341-50.
    View in: PubMed
    Score: 0.034
  116. Differential expression of the early lung cancer detection marker, heterogeneous nuclear ribonucleoprotein-A2/B1 (hnRNP-A2/B1) in normal breast and neoplastic breast cancer. Breast Cancer Res Treat. 2001 Apr; 66(3):217-24.
    View in: PubMed
    Score: 0.032
  117. Relationship of arachidonic acid metabolizing enzyme expression in epithelial cancer cell lines to the growth effect of selective biochemical inhibitors. Cancer Res. 1999 May 01; 59(9):2223-8.
    View in: PubMed
    Score: 0.028
  118. Reflections on early cancer control efforts. J Surg Oncol. 1999 Apr; 70(4):207-8.
    View in: PubMed
    Score: 0.028
  119. Autocrine growth loops dependent on peptidyl alpha-amidating enzyme as targets for novel tumor cell growth inhibitors. Lung Cancer. 1999 Mar; 23(3):209-22.
    View in: PubMed
    Score: 0.028
  120. Expression of heterogeneous nuclear ribonucleoprotein A2/B1 changes with critical stages of mammalian lung development. Am J Respir Cell Mol Biol. 1998 Oct; 19(4):554-62.
    View in: PubMed
    Score: 0.027
  121. Non-small cell lung cancer cycloxygenase activity and proliferation are inhibited by non-steroidal antiinflammatory drugs. Anticancer Res. 1998 Mar-Apr; 18(2A):775-82.
    View in: PubMed
    Score: 0.026
  122. Prospective detection of preclinical lung cancer: results from two studies of heterogeneous nuclear ribonucleoprotein A2/B1 overexpression. Clin Cancer Res. 1997 Dec; 3(12 Pt 1):2237-46.
    View in: PubMed
    Score: 0.026
  123. Antitumor activity of a monoclonal antibody directed against gastrin-releasing peptide in patients with small cell lung cancer. Chest. 1997 Jul; 112(1):256-61.
    View in: PubMed
    Score: 0.025
  124. Purification and characterization of a protein that permits early detection of lung cancer. Identification of heterogeneous nuclear ribonucleoprotein-A2/B1 as the antigen for monoclonal antibody 703D4. J Biol Chem. 1996 May 03; 271(18):10760-6.
    View in: PubMed
    Score: 0.023
  125. Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine. J Clin Oncol. 1996 Mar; 14(3):806-13.
    View in: PubMed
    Score: 0.023
  126. Expression of early lung cancer detection marker p31 in neoplastic and non-neoplastic respiratory epithelium. Lung Cancer. 1996 Feb; 14(1):85-97.
    View in: PubMed
    Score: 0.023
  127. NCI-Navy Medical Oncology Branch cell line data base. J Cell Biochem Suppl. 1996; 24:32-91.
    View in: PubMed
    Score: 0.023
  128. Dipyridamole mediated enhanced antiproliferative activity of 10-ethyl-10-deazaaminopterin (10-EDAM) against human lung cancer cell lines. J Cell Biochem Suppl. 1996; 24:165-72.
    View in: PubMed
    Score: 0.023
  129. Correlation of in vitro drug sensitivity testing results with response to chemotherapy and survival: comparison of non-small cell lung cancer and small cell lung cancer. J Cell Biochem Suppl. 1996; 24:173-85.
    View in: PubMed
    Score: 0.023
  130. Monoclonal antibody alpha IR-3 inhibits non-small cell lung cancer growth in vitro and in vivo. J Cell Biochem Suppl. 1996; 24:269-75.
    View in: PubMed
    Score: 0.023
  131. Differential inactivation of CDKN2 and Rb protein in non-small-cell and small-cell lung cancer cell lines. J Natl Cancer Inst. 1995 May 17; 87(10):756-61.
    View in: PubMed
    Score: 0.022
  132. Analysis of small cell lung cancer cell growth inhibition by 13-cis-retinoic acid: importance of bioavailability. Cell Growth Differ. 1995 May; 6(5):485-92.
    View in: PubMed
    Score: 0.022
  133. Primary and Secondary Prevention of Lung Cancer: an International Association for the Study of Lung Cancer workshop. Lung Cancer. 1995 Mar; 12(1-2):91-103.
    View in: PubMed
    Score: 0.021
  134. Fostering chemopreventive agent development: how to proceed? J Cell Biochem Suppl. 1995; 22:254-9.
    View in: PubMed
    Score: 0.021
  135. The early detection of second primary lung cancers by sputum immunostaining. LCEWDG Investigators. Lung Cancer Early Detection Group. Chest. 1994 Dec; 106(6 Suppl):385S-390S.
    View in: PubMed
    Score: 0.021
  136. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J Clin Oncol. 1994 Oct; 12(10):2022-34.
    View in: PubMed
    Score: 0.021
  137. Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer. Cancer Res. 1994 May 01; 54(9):2496-503.
    View in: PubMed
    Score: 0.020
  138. Pre-operative and post-operative treatments in stage III NSCLC. Lung Cancer. 1994 Mar; 10 Suppl 1:S15-7.
    View in: PubMed
    Score: 0.020
  139. Second IASLC Workshop on Combined Radiotherapy and Chemotherapy Modalities in Lung Cancer. Biological basis of combined therapy. Lung Cancer. 1994 Mar; 10 Suppl 1:S3-5.
    View in: PubMed
    Score: 0.020
  140. Scientific basis for cancer prevention. Intermediate cancer markers. Cancer. 1993 Aug 01; 72(3 Suppl):978-83.
    View in: PubMed
    Score: 0.019
  141. Atrial natriuretic factor and arginine vasopressin production in tumor cell lines from patients with lung cancer and their relationship to serum sodium. Cancer Res. 1993 Jan 01; 53(1):67-74.
    View in: PubMed
    Score: 0.018
  142. Expression of carcinoembryonic antigen and related genes in lung and gastrointestinal cancers. Int J Cancer. 1992 Nov 11; 52(5):718-25.
    View in: PubMed
    Score: 0.018
  143. Randomized trial of neoadjuvant therapy for lung cancer: interim analysis. Ann Thorac Surg. 1992 Jun; 53(6):992-8.
    View in: PubMed
    Score: 0.018
  144. Peripheral airway cell marker expression in non-small cell lung carcinoma. Association with distinct clinicopathologic features. Am J Clin Pathol. 1992 Feb; 97(2):233-43.
    View in: PubMed
    Score: 0.017
  145. p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene. 1992 Jan; 7(1):171-80.
    View in: PubMed
    Score: 0.017
  146. Association between histological type and neuroendocrine differentiation on drug sensitivity of lung cancer cell lines. J Natl Cancer Inst Monogr. 1992; (13):191-6.
    View in: PubMed
    Score: 0.017
  147. Expression of surfactant-associated protein in non-small-cell lung cancer: a discriminant between biologic subsets. J Natl Cancer Inst Monogr. 1992; (13):61-6.
    View in: PubMed
    Score: 0.017
  148. Alpha-amidation of peptide hormones in lung cancer. Cancer Cells. 1991 Dec; 3(12):504-10.
    View in: PubMed
    Score: 0.017
  149. ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. Cancer Res. 1991 Sep 15; 51(18):4999-5002.
    View in: PubMed
    Score: 0.017
  150. Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines. Oncogene. 1991 Aug; 6(8):1353-62.
    View in: PubMed
    Score: 0.017
  151. Cross validation of cluster analysis using immunostained multi-tissue tumour block slides. Br J Cancer Suppl. 1991 Jun; 14:60-3.
    View in: PubMed
    Score: 0.016
  152. Nonrandom structural and numerical chromosome changes in non-small-cell lung cancer. Genes Chromosomes Cancer. 1991 May; 3(3):168-88.
    View in: PubMed
    Score: 0.016
  153. [Psi 13,14] bombesin analogues inhibit growth of small cell lung cancerin vitro and in vivo. Cancer Res. 1991 Apr 01; 51(7):1798-802.
    View in: PubMed
    Score: 0.016
  154. Peripheral airway cell differentiation in human lung cancer cell lines. Cancer Res. 1990 Sep 01; 50(17):5481-7.
    View in: PubMed
    Score: 0.016
  155. Outcome of patients with small-cell lung cancer: effect of changes in staging procedures and imaging technology on prognostic factors over 14 years. J Clin Oncol. 1990 Jun; 8(6):1042-9.
    View in: PubMed
    Score: 0.015
  156. Biological, molecular, and clinical markers for the diagnosis and typing of lung cancer. Immunol Ser. 1990; 53:453-68.
    View in: PubMed
    Score: 0.015
  157. Antibody 624H12, which detects lung cancer at early stages, recognizes a sugar sequence in the glycosphingolipid difucosylneolactonorhexaosylceramide (V3FucIII3FunLc6Cer). Arch Biochem Biophys. 1989 Nov 15; 275(1):309-14.
    View in: PubMed
    Score: 0.015
  158. MDR1 gene expression in lung cancer. J Natl Cancer Inst. 1989 Aug 02; 81(15):1144-50.
    View in: PubMed
    Score: 0.014
  159. Neuroendocrine differentiation in endocrine and nonendocrine lung carcinomas. Am J Clin Pathol. 1988 Dec; 90(6):641-52.
    View in: PubMed
    Score: 0.014
  160. A novel bombesin receptor antagonist inhibits autocrine signals in a small cell lung carcinoma cell line. Biochem Biophys Res Commun. 1988 Nov 15; 156(3):1383-9.
    View in: PubMed
    Score: 0.014
  161. Identifying prognostic factors in binary outcome data: an application using liver function tests and age to predict liver metastases. Stat Med. 1988 Aug; 7(8):843-56.
    View in: PubMed
    Score: 0.014
  162. Insulin-like growth factor-I can mediate autocrine proliferation of human small cell lung cancer cell lines in vitro. J Clin Invest. 1988 Jul; 82(1):354-9.
    View in: PubMed
    Score: 0.013
  163. Growth factor effects on small cell lung cancer cells using a colorimetric assay: can a transferrin-like factor mediate autocrine growth? Exp Cell Biol. 1988; 56(1-2):74-85.
    View in: PubMed
    Score: 0.013
  164. Gastrin-releasing peptide and other autocrine growth factors in lung cancer: pathogenetic and treatment implications. Important Adv Oncol. 1988; 55-64.
    View in: PubMed
    Score: 0.013
  165. Markedly different antibody responses to immunized small cell and non-small cell lung cancer cells. Cancer Res. 1987 Oct 01; 47(19):5009-13.
    View in: PubMed
    Score: 0.013
  166. Glycolipid antigen expression in human lung cancer. Cancer Res. 1986 Sep; 46(9):4751-5.
    View in: PubMed
    Score: 0.012
  167. Heterogeneity of cell surface antigen expression of human small cell lung cancer detected by monoclonal antibodies. Cancer Res. 1986 May; 46(5):2633-8.
    View in: PubMed
    Score: 0.012
  168. Molecular genetic analysis reveals chromosomal deletion, gene amplification, and autocrine growth factor production in the pathogenesis of human lung cancer. Cold Spring Harb Symp Quant Biol. 1986; 51 Pt 2:843-53.
    View in: PubMed
    Score: 0.011
  169. Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. Nature. 1985 Aug 29-Sep 4; 316(6031):823-6.
    View in: PubMed
    Score: 0.011
  170. Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA in human small-cell lung cancer. J Exp Med. 1985 May 01; 161(5):1135-51.
    View in: PubMed
    Score: 0.011
  171. Improved antigen detection in ethanol-fixed cytologic specimens. A modified avidin-biotin-peroxidase complex (ABC) method. Diagn Cytopathol. 1985 Apr-Jun; 1(2):133-6.
    View in: PubMed
    Score: 0.011
  172. Autocrine growth factors in human small cell lung cancer. Cancer Surv. 1985; 4(4):707-27.
    View in: PubMed
    Score: 0.011
  173. Analysis of human small cell lung cancer differentiation antigens using a panel of rat monoclonal antibodies. Cancer Res. 1984 May; 44(5):2052-61.
    View in: PubMed
    Score: 0.010
  174. Expression of heterogeneous nuclear ribonucleoprotein A2/B1 in bronchial epithelium of chronic smokers. Clin Cancer Res. 1998 Jul; 4(7):1631-40.
    View in: PubMed
    Score: 0.007
  175. Detection of K-ras oncogene mutations by polymerase chain reaction-based ligase chain reaction. Anal Biochem. 1996 Aug 01; 239(2):153-9.
    View in: PubMed
    Score: 0.006
  176. Insulin-like growth factor expression in human cancer cell lines. J Biol Chem. 1996 May 10; 271(19):11477-83.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.